Editorial: Inflammation, Disease‐Modifying Antirheumatic Drugs, Lipids, and Cardiovascular Risk in Rheumatoid Arthritis

Publisher： John Wiley & Sons Inc

E-ISSN： 2326-5205|67|2|327-329

ISSN： 2326-5191

Source： ARTHRITIS & RHEUMATOLOGY, Vol.67, Iss.2, 2015-02, pp. : 327-329

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease‐Modifying Antirheumatic Drugs

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 12, 2015-12 ,pp. : 1671-1678

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use and Spending for Biologic Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 9, 2015-09 ,pp. : 1210-1218

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and retention of combination triple disease‐modifying anti‐rheumatic drugs in new‐onset rheumatoid arthritis

By  

INTERNAL MEDICINE JOURNAL, Vol. 45, Iss. 12, 2015-12 ,pp. : 1266-1273

John Wiley & Sons Inc

Access to resources Recommend Favorite

Medication Persistence of Disease‐Modifying Antirheumatic Drugs and Anti–Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil

By  

ARTHRITIS CARE AND RESEARCH, Vol. 68, Iss. 10, 2016-10 ,pp. : 1489-1496

John Wiley & Sons Inc

Access to resources Recommend Favorite

Disease‐Modifying Antirheumatic Drug Use and the Risk of Incident Hyperlipidemia in Patients With Early Rheumatoid Arthritis: A Retrospective Cohort Study

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 4, 2015-04 ,pp. : 457-466

John Wiley & Sons Inc

Access to resources Recommend Favorite